Key result
Bariatric surgery for class 1 obesity is linked to ~89% excess weight loss at 5 years.
Why the study?
There is a paucity of literature exploring the role of bariatric surgery in patients with class 1 obesity.
Does bariatric surgery improve weight loss and obesity-related comorbidities in patients with class 1 obesity?
Cohort (n=37)
No
Does bariatric surgery improve weight loss and obesity-related comorbidities in patients with class 1 obesity?
Bariatric surgery in patients with class 1 obesity demonstrates long-term efficacy for weight loss and remission of cardiometabolic comorbidities.
Answers are grounded in this paper and cite their sources.
May warrant individualized consideration in class 1 obesity; leaves open routine adoption pending randomized trials.
BACKGROUND: There is a paucity of literature exploring the role of bariatric surgery in class 1 obesity. We evaluated the 5-year outcomes after bariatric surgery in patients with class 1 obesity, assessing weight loss, resolution/reduction of obesity-related comorbidities, morbidity and mortality. METHODS: We performed a single-centre retrospective analysis of patients who underwent bariatric surgery (laparoscopic sleeve gastrectomy [LSG] or laparoscopic Roux-en-Y gastric bypass [LRYGB)]) for class 1 obesity (body mass index [BMI] 30.0-34.9) between January 2012 and February 2019. RESULTS: Thirty-seven patients (35 [95%] female, mean age 44.5 yr [standard error (SE) 11.3 yr], mean preoperative BMI 33.1) were included, of whom 32 underwent LSG and 5 underwent LRYGB. Thirty-five patients were followed for 5 years post-operatively, achieving a mean BMI of 25.6 (SE 1.2) and excess weight loss of 89.4% (SE 15.1%). Remission of hypertension was achieved in 5 of 12 patients (42%), and remission of dyslipidemia was achieved in 7 of 11 patients (64%). Of the 11 patients with diabetes, 7 underwent LSG and 4, LRYGB. At 5 years postoperatively, the mean glycosylated hemoglobin concentration was 6.3%. Four patients in the LSG group developed de novo reflux, 1 patient required conversion to LRYGB, and 1 patient with sleeve stenosis required endoscopic dilatation. There were no deaths in either patient group. CONCLUSION: At our centre, bariatric surgery for class 1 obesity was safe and had long-term efficacy, with remission or reduction of related comorbidities. Prospective controlled trials are required to confirm these results.
No takes yet. Share an insight, caveat, or question.
Studer et al. (2022) conducted a cohort in Class 1 obesity (n=37). Bariatric surgery (LSG or LRYGB) was evaluated on Excess weight loss at 5 years. Bariatric surgery for class 1 obesity resulted in a mean excess weight loss of 89.4% and a mean BMI of 25.6 at 5 years, alongside remission or reduction of obesity-related comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: